Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11661453B2 · kind B2 · utility
1Cited by
11References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2018 |
| Grant date | May 30, 2023 |
| Priority date | — |
| Expiry date | May 20, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.